S

Sironax

Biotech & Life Sciences · Changping District, China · Founded 2017

Sironax is a clinical-stage biotechnology firm established in 2017 by co-founders Dr. Xiaodong Wang and Dr. Zhiyuan Zhang. The company's scientific foundation is built upon Dr. Wang's pioneering research over two decades into the mechanisms of programmed cell death and its connection to aging. This deep scientific expertise underpins Sironax's strategy to develop therapies that target the root causes of age-related degenerative diseases. The company's business model is centered on the discovery, in-house development, and clinical progression of novel drug candidates. Sironax has secured substantial financial backing, raising over $300 million to date, including a significant $200 million Series B financing round in August 2022. This funding is being used to advance its clinical pipeline and expand research and development operations. The company's strategy also includes strategic partnerships, such as a July 2025 agreement with Novartis, granting an exclusive option to acquire Sironax's Brain Delivery Module (BDM) platform, a technology designed to help therapeutics cross the blood-brain-barrier. Sironax's therapeutic pipeline focuses on key pathways of cellular aging, including regulated cell death, neuroinflammation, and metabolic changes. Its portfolio consists of multiple programs targeting conditions like neurodegenerative diseases, muscular weakness, and metabolic disorders. Several drug candidates, all designed and synthesized in-house, have advanced to clinical trials. Notable assets include RIPK1 (receptor-interacting serine/threonine-protein kinase 1) inhibitors, such as SIR0365, which has completed Phase 1b studies, and SIR2446, which has entered Phase 1a trials. Another candidate, SIR2501, recently completed a Phase 1 study in Australia and China for potential application in neurodegenerative diseases like ALS. Operating globally with a growing team of over 140 employees in China, the U.S., and Australia, Sironax aims to shift the treatment paradigm for a patient population currently served mostly by palliative care. Keywords: age-related degenerative diseases, clinical-stage biotechnology, programmed cell death, neurodegeneration, neuroinflammation, RIPK1 inhibitors, small molecule drugs, biologics, drug discovery, therapeutics development, blood-brain-barrier, metabolic disorders, muscular disorders, SIR0365, SIR2446, SIR2501, Xiaodong Wang, clinical trials, pharmaceutical partnerships, venture capital funding